Moderna (MRNA, Financial) shares soared over 9.4%, reaching a peak of $56.695 after releasing their third-quarter financial results. The company reported a revenue of $1.9 billion, marking a 5.5% increase year over year, surpassing market expectations of $1.3 billion.
In a surprising turn, Moderna recorded an earnings per share of 3 cents, compared to a loss of $9.53 per share in the same period last year. Analysts had anticipated a loss of $1.94 per share. The company has reaffirmed its full-year 2024 product sales guidance, projecting between $3 billion and $3.5 billion.
